Cargando…
Advances in Anti-IgE Therapy
Omalizumab depletes free IgE in the blood and interstitial space and inhibits IgE binding to FcεRI on basophils, mast cells, and dendritic cells. We stopped omalizumab treatment after four years. Recurrences of urticaria symptoms were found to be higher in patients with chronic urticaria than recurr...
Autor principal: | Yalcin, Arzu Didem |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436440/ https://www.ncbi.nlm.nih.gov/pubmed/26075226 http://dx.doi.org/10.1155/2015/317465 |
Ejemplares similares
-
An Overview of the Effects of anti-IgE Therapies
por: Yalcin, Arzu Didem
Publicado: (2014) -
Levofloxacin Induced Toxic Epidermal Necrolysis: Successful Therapy with Omalizumab (Anti-IgE) and Pulse Prednisolone
por: Uzun, Rusen, et al.
Publicado: (2016) -
Anti-IgE therapy for IgE-mediated allergic diseases: from neutralizing IgE antibodies to eliminating IgE(+) B cells
por: Hu, Jiayun, et al.
Publicado: (2018) -
Chronic Rhinosinusitis with Nasal Polyps: Targeting IgE with Anti-IgE Omalizumab Therapy
por: Kariyawasam, Harsha H, et al.
Publicado: (2020) -
Environmental and occupational respiratory diseases – 1039. Clinical course and side effects of anti-IgE monoclonal antibody in patients with severe persistent asthma
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)